These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 14702244)

  • 21. Important steps in the development of cognitive-enhancing drugs in schizophrenia.
    Buchanan RW
    Am J Psychiatry; 2006 Nov; 163(11):1867-9. PubMed ID: 17074932
    [No Abstract]   [Full Text] [Related]  

  • 22. [Cognitive deficits in schizophrenia and other psychotic disorders].
    Fagerlund B; Glenthøj BY
    Ugeskr Laeger; 2008 Nov; 170(46):3770-2. PubMed ID: 19014728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cognitive impairment in late life schizophrenia: a suitable case for treatment?
    Howard R
    Int J Geriatr Psychiatry; 1998 Jun; 13(6):400-4. PubMed ID: 9658275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A short version of the measurement and treatment research to improve cognition in schizophrenia consensus cognitive battery.
    Kaneda Y; Sora I
    Schizophr Res; 2013 Nov; 150(2-3):600-1. PubMed ID: 24091033
    [No Abstract]   [Full Text] [Related]  

  • 25. The MATRICS consensus cognitive battery (MCCB): co-norming and standardization in Spain.
    Rodriguez-Jimenez R; Bagney A; Garcia-Navarro C; Aparicio AI; Lopez-Anton R; Moreno-Ortega M; Jimenez-Arriero MA; Santos JL; Lobo A; Kern RS; Green MF; Nuechterlein KH; Palomo T
    Schizophr Res; 2012 Feb; 134(2-3):279-84. PubMed ID: 22192501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cognitive impairment as a target for pharmacological treatment in schizophrenia.
    Davidson M; Keefe RS
    Schizophr Res; 1995 Sep; 17(1):123-9. PubMed ID: 8541245
    [No Abstract]   [Full Text] [Related]  

  • 27. [Cognitive deficit in schizophrenia: MATRICS Consensus Cognitive Battery].
    Rodríguez-Jiménez R; Bagney A; Moreno-Ortega M; García-Navarro C; Aparicio AI; López-Antón R; de la Oliva J; Jiménez-Arriero MÁ; Santos JL; Lobo A; Palomo T
    Rev Neurol; 2012 Nov; 55(9):549-55. PubMed ID: 23111994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Functionality as a goal in the treatment of schizophrenia].
    García B;
    Actas Esp Psiquiatr; 2002; 30(5):312-25. PubMed ID: 12372228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating the effects of antipsychotics on cognition in schizophrenia. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():35-40. PubMed ID: 9766618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Computer-assisted cognitive rehabilitation reduces negative symptoms in the severely mentally ill.
    Bellucci DM; Glaberman K; Haslam N
    Schizophr Res; 2003 Feb; 59(2-3):225-32. PubMed ID: 12414079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cognitive deficits in adolescents with schizophrenia undergoing antipsychotic treatment.
    Chabrol H; Peresson G; Bonnet D
    Am J Psychiatry; 1999 Mar; 156(3):497-8. PubMed ID: 10080578
    [No Abstract]   [Full Text] [Related]  

  • 32. Cognitive deficits as treatment targets in schizophrenia.
    Gold JM
    Schizophr Res; 2004 Dec; 72(1):21-8. PubMed ID: 15531404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Approaches to the development of the Japanese academic version of the MATRICS Consensus Cognitive Battery].
    Sato T; Sora I
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2011 Nov; 31(5-6):241-4. PubMed ID: 22256613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cognitive dysfunction in schizophrenia.
    Lublin H
    Acta Psychiatr Scand Suppl; 2001; (408):5-9. PubMed ID: 11730073
    [No Abstract]   [Full Text] [Related]  

  • 35. The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia.
    Marder SR
    Dialogues Clin Neurosci; 2006; 8(1):109-13. PubMed ID: 16640121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative.
    Carter CS; Barch DM; Buchanan RW; Bullmore E; Krystal JH; Cohen J; Geyer M; Green M; Nuechterlein KH; Robbins T; Silverstein S; Smith EE; Strauss M; Wykes T; Heinssen R
    Biol Psychiatry; 2008 Jul; 64(1):4-10. PubMed ID: 18466880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Schizophrenia and cognition: long-standing and current issues].
    Azorin JM; Da Fonseca D; Fakra E
    Encephale; 2011 Dec; 37 Suppl 2():S93-4. PubMed ID: 22212848
    [No Abstract]   [Full Text] [Related]  

  • 38. Doubtful association of antipsychotic polypharmacy and high dosage with cognition in chronic schizophrenia.
    Kontis D; Theochari E; Kleisas S; Kalogerakou S; Andreopoulou A; Psaras R; Makris Y; Karouzos C; Tsaltas E
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1333-41. PubMed ID: 20691745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.
    Green MF; Nuechterlein KH; Kern RS; Baade LE; Fenton WS; Gold JM; Keefe RS; Mesholam-Gately R; Seidman LJ; Stover E; Marder SR
    Am J Psychiatry; 2008 Feb; 165(2):221-8. PubMed ID: 18172017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical constructs and therapeutic discovery.
    Carpenter WT
    Schizophr Res; 2004 Dec; 72(1):69-73. PubMed ID: 15531408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.